Yahoo Finance Little Green Pharma Full Year 2024 Earnings: EPS Misses Expectations
Little Green Pharma (ASX:LGP) Full Year 2024 Results
Key Financial Results
Revenue: AU$25.6m (up 29% from FY 2023).
Net loss: AU$8.15m (loss narrowed by 4.7% from FY 2023).
AU$0.027 loss per share (improved from AU$0.034 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Little Green Pharma EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 49% growth forecast for the Pharmaceuticals industry in Australia.
Performance of the Australian Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Little Green Pharma.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
